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Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is an inhibitor of megakaryopoi-
esis and platelet function. Recently, PACAP deficiency was observed in children with
nephrotic syndrome (NS), associated with increased platelet count and aggregability and
increased risk of thrombosis. To further study PACAP deficiency in NS, we used transgenic
Tg(cd41:EGFP) zebrafish with GFP-labeled thrombocytes. We generated two models for
congenital NS, a morpholino injected model targeting nphs1 (nephrin), which is mutated in
the Finnish-type congenital NS. The second model was induced by exposure to the nephro-
toxic compound adriamycin. Nephrin RNA expression was quantified and zebrafish embryos
were live-screened for proteinuria and pericardial edema as evidence of renal impairment.
Protein levels of PACAP and its binding-protein ceruloplasmin were measured and GFP-
labeled thrombocytes were quantified. We also evaluated the effects of PACAP morpholino
injection and the rescue effects of PACAP-38 peptide in both congenital NS models. Nephrin
downregulation and pericardial edema were observed in both nephrin morpholino injected
and adriamycin exposed congenital NS models. However, PACAP deficiency was demon-
strated only in the adriamycin exposed condition. Ceruloplasmin levels and the number of
GFP-labeled thrombocytes remained unchanged in both models. PACAP morpholino injec-
tions worsened survival rates and the edema phenotype in both congenital NS models while
injection with human PACAP-38 could only rescue the adriamycin exposed model. We
hereby report, for the first time, PACAP deficiency in a NS zebrafish model as a conse-
quence of adriamycin exposure. However, distinct from the human congenital NS, both zeb-
rafish models retained normal levels of ceruloplasmin and thrombocytes. We further extend
the renoprotective effects of the PACAP-38 peptide against adriamycin toxicity in zebrafish.
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Introduction
Nephrotic syndrome (NS) is a disease of the glomerular filtration barrier, characterized by
severe proteinuria, hypoalbuminemia, edema, and hyperlipidemia [1]. Congenital NS (CNS) is
a severe form of NS, manifesting within 3 months of life with profound edema and proteinuria
being present intrauterine. CNS is rarely the result of non-genetic causes, such as intrauterine
infections, but most frequently, it is caused by genetic mutations in one of the following genes:
NPHS1, NPHS2, WT1, LAMB2 or PLCE1 [2,3]. NPHS1 encodes for nephrin, a structural com-
ponent of the slit diaphragm [4], which plays a role in intracellular signaling and interacts with
the podocyte cytoskeleton [5]. NPHS1 mutations and subsequent disruption of the slit dia-
phragm cause CNS of the Finnish-type, a common and severe form of CNS with extremely
pronounced proteinuria.
Patients with NS have an increased risk of thromboembolic events, both deep venous and
arterial thrombosis [6,7]. Elevated levels of prothrombotic factors such as factor V, factor VIII,
von Willebrand factor and fibrinogen, and decreased levels of antithrombotic factors such as
antithrombin III, protein C and protein S were described in NS patients and probably underlie
the increased risk of deep venous thrombosis [6]. However, the fact that the risk of both
venous and arterial thrombosis is elevated in NS, points to an additional role for blood plate-
lets. Indeed, increased platelet counts and hyperaggregability were repeatedly observed in NS
patients [8].
Recently, we found evidence that deficiency of pituitary adenylate cyclase activating poly-
peptide (PACAP) plays a role in the increased platelet count and hyperaggregability in CNS
[9]. PACAP is a highly conserved neuropeptide [10,11]. In human plasma, PACAP is bound to
its carrier protein ceruloplasmin (132 kDa), which prevents it from rapid degradation [12].
PACAP is widely expressed in the nervous system, but also in several peripheral tissues, where
it takes part in diverse biological processes [11]. PACAP can bind three different G-protein-
coupled receptors: the PAC1 receptor, which is PACAP specific, and the VPAC1 and VPAC2
receptors, which bind both vasoactive intestinal peptide (VIP) and PACAP and are coupled to
adenylyl cyclase [13–15]. Interestingly, PACAP was identified as an inhibitor of megakaryo-
poiesis and platelet activation. Freson et al studied patients with elevated PACAP plasma levels
due to a partial trisomy 18p and transgenic mice with megakaryocyte-specific PACAP overex-
pression [16,17]. They found that PACAP inhibits megakaryopoiesis and platelet function and
prolongs the bleeding time, via activation of adenylyl cyclase-coupled VPAC1 receptors on
megakaryocytes and platelets.
The opposite phenotype with stimulation of platelet function and megakaryopoiesis was
obtained in wild-type mice injected with a PACAP antagonist PACAP(6–38) or a monoclonal
inhibitory antibody against PACAP or its receptor VPAC1, as well as in PACAP knockout
mice. Peeters et al further showed a thrombopoietic effect of VPAC1 inhibition in thrombocy-
topenia murine models [18]. We recently reported urinary losses of PACAP and ceruloplas-
min in NS children, which was more pronounced in children with the CNS of the Finnish type
than in children with idiopathic NS (INS); however, platelet hyperaggregability during
nephrotic state was equally present [9]. We further confirmed that megakaryopoiesis and
platelet aggregability were increased in CNS patients during the nephrotic state in comparison
to the non-nephrotic state after bilateral nephrectomy and that this effect could be reversed by
the addition of recombinant PACAP-38 [9].
To support our hypothesis that PACAP deficiency is the cause of increased megakaryopoi-
esis in CNS, and to further study the mechanisms behind this effect, we sought a NS animal
model. Constitutive nephrin knockout mice are not available as the animals die within 24
hours after birth [19]. Zebrafish larvae are currently widely used in kidney research as the
PACAP in nephrotic syndrome zebrafish
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structure of the glomerular filtration barrier is similar to the mammalian filter, with the pres-
ence of fenestrated endothelial cells, a glomerular basement membrane and podocytes with a
slit diaphragm. Moreover, in zebrafish, a complete maturation of the glomerulus is observed
within 3 days post fertilization (3 dpf) [20].
For our study, we used two previously characterized NS zebrafish models [21,22]. The first
was obtained by injection of a morpholino targeting nephrin (nphs1) [21]. Nephrin depleted
zebrafish were previously shown to have podocyte foot processes effacement and absent slit dia-
phragms, in accordance with observations for Finnish-type CNS in humans. Moreover, due to
loss of the podocyte barrier function, nephrin depleted embryos developed a phenotype of pro-
teinuria and pericardial edema at 4 dpf [21]. The second NS zebrafish model was obtained by
exposure to low concentrations of adriamycin [22]. Adriamycin exposure leads to podocyte
developmental defects and decreased nephrin expression, with subsequent functional
impairment of the glomerular filtration barrier, causing proteinuria and pericardial edema,
similar to the observations for human CNS. We established these two NS models in Tg(cd41:
EGFP) transgenic zebrafish with GFP-labeled thrombocytes, previously used to study thrombo-
cyte formation [23]. The aim of this study was to investigate whether these CNS zebrafish mod-
els develop PACAP deficiency and increased thrombocyte numbers as found in human CNS.
Material and methods
Embryo collection
All zebrafish experiments and protocols were approved by the Ethical Committee of the Cath-
olic University of Leuven. Tg(cd41:EGFP) transgenic zebrafish embryos were a gift from Dr. L.
Zon (Hematology Division, Brigham and Women’s Hospital’s, Boston, MA, USA). Embryos
were kept at 28.5˚C in egg water medium (Instant Ocean Sea Salts, 60 μg/ml, and methylene
blue, 0.3 ppm).
Morpholino injection
Tg(cd41:EGFP) transgenic Danio rerio embryos [23] were injected at the one-cell stage with an
exon splice donor sites targeting morpholino for nephrin (5’-CGCTGTCCATTACCTTTCAG
GCTCC-3’) at 50, 100 and 200 μM, as previously described22. The morpholino was diluted in
an injection solution (0.5% Phenol red (Sigma, St-Louis, MO, USA) 1/10 in NaCl 0.9% (v/v)).
Off-target effects were excluded by the inclusion of standard control morpholino (5’- CCTC
TTACCTCAGTTACAATTTATA-3’) injected embryos. Since PACAP is translated by two
genes in zebrafish (adcyap1a and adcyap1b), we injected splicing morpholinos for both genes
together in the PACAP suppression experiments (adcyap1a: 5’- CCTCCTCTGCGTTAGAGA
AATAGGA-3’ and adcyap1b: 5’- CCTCCGCTGCAAATATAGGAACTAT-3’). PACAP,
nephrin, and control morpholinos were all obtained from Gene-Tools LLC (Philomath, OR,
USA).
Embryo exposure to adriamycin
Tg(cd41:EGFP) transgenic zebrafish embryos [23] were incubated in either free medium, 10 or
30 μM of adriamycin (Sigma) starting from 9 hpf as previously described [22]. Adriamycin
was removed from the medium after 48 hours (at 57 hpf). Embryos were next washed several
times with medium and further immersed in the adriamycin-free medium. PACAP rescue
experiments for both CNS models were performed through the injection of recombinant
human PACAP-38 (Bachem, Bubendorf, Switzerland). The human peptide has 85% identity
and 94% similarity with zebrafish PACAP (S1 Fig).
PACAP in nephrotic syndrome zebrafish
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Phenotype characterization
Fluorescent microscopy was used for live-screening of embryos/larvae at 24, 48, 72, 96 and 120
hpf. The number of thrombocytes in the caudal hematopoietic tissue (CHT) of zebrafish
embryos/larvae was recorded through the detection of GFP-labeled thrombocytes. Images
were captured with a Zeiss Axiocam HR camera using AxioVision software 4.8 (Carl Zeiss,
Jena, Germany). Pixel intensity of fluorescent pictures was measured using ImageJ software
(http://rsbweb.nih.gov/ij/).
Evaluation of glomerular blood filtration
A qualitative assay was performed to evaluate glomerular blood filtration, as previously
described [24]. Rhodamine-labeled 70 kDa-dextran (2 nl of 50 mg/ml) (Sigma) was injected
into the cardiac venous sinus of 75 hpf old larvae. Images were captured 5 hours after injection
using a Zeiss Axiocam HR camera and AxioVision software 4.8 (Carl Zeiss). Fluorescence
intensity in the retinal vascular bed was measured using ImageJ software.
RNA isolation, reverse transcription PCR, and quantitative real-time
PCR
Total RNA was extracted from at least 15 zebrafish embryos per sample at various stages of
development using Trizol Reagent (Invitrogen, Waltham, USA). RNA concentration was mea-
sured using Nanodrop 2000c (Thermo Scientific, Waltham, USA). cDNA was produced from
1 μg of RNA using SuperScriptR III reverse transcriptase (Life Technologies, Carlsbad, USA),
oligo (dT) primers, random hexamer primers and dNTP mix (Invitrogen). Pixel intensities of
reverse transcription PCR (RT-PCR) bands were measured using ImageJ software. Quantita-
tive real-time PCR (qPCR) was performed with Platinum SYBR Green qPCR mix (Invitrogen).
Sequences of forward and reverse primers were: nphs1 (Fw) 5’-GCAAGCTACATGTATGTAG
ACGTGT-3’ and nphs1 (Rv) 5’-TCCTGTGAAATGCTGCTGGTGTC-3’, adcyap1a (Fw) 5’-
CGCCTCTGAGTTACCCGAAAA-3’ and adcyap1a (Rv) 5’-TAGCGAGCCGCCGTCCTTTG-
3’, adcyap1b (Fw) 5’-TCAGGGAAGAGGTGCTGTGAGGA-3’ and adcyap1b (Rv) 5’-
CATCTGTTTTCGGTAGCGACTGT-3’, vip (Fw) 5’-GGCTCTTCACAAGCGGATAC-3’ and
vip (Rv) 5’-ATCATCACTGACCCGCTTTC-3’. As a reference gene, we used Eukaryotic trans-
lation elongation factor 1 alpha 1, like 1 (eef1a1l1) (Fw) 5’-CTTCTCAGGCTGACTGTGC-3’
and eef1a1l1 (Rv) 5’-CCGCTAGCATTACCCTCC-3’ [25].
Immunoblot analysis
Protein lysates were obtained from control versus nephrin morphants and from adriamycin
non-exposed versus exposed zebrafish larvae. Blots were incubated with a rabbit polyclonal
anti-PACAP antibody (produced in our laboratory, as previously described) [16], a rabbit
monoclonal anti-ceruloplasmin antibody (Dako, Glostrup, Denmark), a goat polyclonal anti-
GFP antibody (Rockland Immunochemicals, Gilbertsville, USA) and a rabbit monoclonal
anti-β-actin antibody (Cell Signaling Technology, Boston, USA). Secondary anti-rabbit and
anti-goat antibodies were from Dako. Blots were stained with Western blotting electrochemi-
luminescence (ECL) detection reagent (Thermo Scientific, Rockford, USA). Detection of sig-
nal and measuring of band intensity were performed with ImageJ software. The band
intensities of PACAP, ceruloplasmin, and GFP were corrected for the band intensities of the
loading control β-actin [26] and were expressed as a percentage of the control condition. All
Western blots were performed at multiple time points during the first 6 days of development
and at least in duplicate.
PACAP in nephrotic syndrome zebrafish
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Flow cytometric analysis of CD41 positive thrombocytes
Control versus nephrin morpholino injected Tg(cd41:EGFP) transgenic embryos were dechor-
ionated if not hatched at 72 hpf, and digested with 0.02% trypsin/EDTA for 15 minutes at
28˚C. Each sample was pipetted 10 times up and down, for getting a single cell suspension.
Cells were filtered through a 40 μm cell strainer and centrifuged (770 g for 10 minutes at room
temperature). Pellets were then resuspended in phosphate buffered saline (PBS). The Cell Diva
software was used for two-color immunofluorescence acquisition on a FACSCanto II flow
cytometer (BD Biosciences, San Diego, USA) and for data analysis determining the percentage
of GFP-positive thrombocytes.
Statistical analysis
Statistical analysis was performed by the SPSS Statistics software, ver. 22 (IBM, Armonk, New
York, USA). Continuous variables were compared using two-tailed Student’s t-test for
unpaired data. P< 0.05 was regarded as statistically significant.
Results
Nephrin depleted CNS zebrafish model
The first CNS zebrafish model was obtained by injection of Tg(cd41:EGFP) transgenic zebra-
fish with a splice site morpholino targeting nphs1 gene [21]. The zebrafish embryos were live-
screened for the nephrotic phenotype of pericardial edema at 3 and 5 dpf and were divided
into 3 different categories: embryos with a normal phenotype, embryos with visible pericardial
edema and severe dysmorphic or dead embryos (Fig 1A). A phenotype of pericardial edema
was obtained at 5 dpf in only 6, 20 and 28% of embryos after nephrin morpholino injections of
50, 100 and 200 μM, respectively (Fig 1B). Phenotypes at 3 dpf were basically similar to those
observed at 5 dpf. For increasing concentrations of nephrin morpholino, an increasing per-
centage of embryos showed a severely dysmorphic phenotype or died. All further experiments
were performed with 100 μM nephrin morpholino. RT-PCR was performed using total RNA
extracted from nephrin morpholino and control morpholino zebrafish at 24, 48 and 72 hpf.
Reduced nephrin expression (389 bp) was seen in RNA samples extracted from nephrin mor-
phants compared to control embryos (Fig 1C). Quantification of nephrin expression in
nephrin morphants was 57.2, 57.6 and 33.0% compared to controls at 24, 48 and 72 hpf,
respectively, P < 0.05 (Fig 1D). Abnormal RT-PCR bands of 272 and 1070 bp were only
detected for the splice nephrin morpholino injected embryos resulting from exon deletion and
retention of an adjacent intron, respectively.
Nephrin depleted embryos showed significant downregulation of adcyap1a after 48 and 72
hpf compared to control morpholino, while the second PACAP translating gene (adcyap1b)
showed no significant difference (S2 Fig). Since both VIP and PACAP act on the VPAC1
receptors with a similar affinity [27], we also tested for the expression of the zebrafish vip gene
using the same samples and detected its downregulation at 48 and 72 hpf similar to adcyap1a
(S3 Fig). All three genes tend to be upregulated normally during the first three days of
development.
Nephrin depleted embryos with visible pericardial edema were selected to further study
PACAP and ceruloplasmin expression using Western blot analysis of total embryo lysates. No
differences in PACAP levels were observed in nephrin depleted versus controls embryos (Fig
2). Western blot for ceruloplasmin also showed no significant difference in nephrin depleted
and control embryos at 3 dpf. Western blots for PACAP and ceruloplasmin were repeated at 5
dpf with similar results.
PACAP in nephrotic syndrome zebrafish
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Tg(cd41:EGFP) transgenic zebrafish were next used to study the effect of nephrin depletion
on thrombocyte formation. Fluorescence microscopy did not show a difference between GFP-
labeled thrombocytes in nephrin morpholino injected (100 μM) versus control embryos at 3
dpf (Fig 3A). Quantification of GFP expression via Western blot analysis also revealed no dif-
ferences in thrombocyte numbers (Fig 3B). Finally, flow cytometric analysis of lysates from
whole zebrafish embryos did not show any differences in the number of GFP-positive throm-
bocytes (Fig 3C). Western blot and flow cytometry were repeated at 5 dpf with similar results.
In order to evaluate if PACAP could have an effect on the phenotype of nephrin depleted
embryos, we conducted independent series of experiments through the injection of zebrafish
PACAP morpholinos (adcyap1a and adcyap1b) in embryos with either nphs1 morpholino or
control morpholino injected (approximately 100 embryos per group). As seen in Fig 4, co-
injection of both PACAP morpholinos had a harmful effect compared to control morpholino-
injected embryos and a devastating effect on nphs1 morpholino injected embryos (Fig 4A and
4B). On the other hand, human PACAP-38 could rescue the phenotype of embryos injected
Fig 1. Phenotype and nephrin expression in nephrin depleted zebrafish. (A) Three categories of phenotypes
were defined in nephrin morpholino injected embryos: embryos without edema (normal), embryos with visible
pericardial edema (white arrow) and dysmorphic or dead embryos. Pictures were taken at 5 dpf. (B) 80 embryos
per condition were live-screened at 5 dpf and assigned to a phenotype category. Increasing concentrations of the
injected nephrin morpholino were associated with an increasing percentage of embryos with pericardial edema,
but also with increased numbers of severely dysmorphic or dead embryos. (C) RT-PCR was performed using total
RNA extracted from nephrin morpholino (100 μM) and control morpholino injected embryos at 24, 48 and 72 hpf.
Reduced expression of normal nephrin (389 bp) was found in the nephrin depleted versus control embryos.
Moreover, injection of nephrin morpholino induced alternative splicing resulted in 272 and 1070 bp fragments,
resulting from an exon deletion and a retained intron, respectively. (D) Quantitation of nphs1 RNA expression in
control versus nephrin morpholino injected larvae after 24, 48 and 72 h of injection. M, marker; Mo, nephrin
morpholino injected; Co, control morpholino injected.
https://doi.org/10.1371/journal.pone.0182100.g001
PACAP in nephrotic syndrome zebrafish
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with adcyap1a and adcyap1b morpholinos, but not of those injected with nphs1 morpholino
(Fig 4C and 4D).
Adriamycin exposed CNS zebrafish model
The adriamycin model of NS in zebrafish was previously described [22]. We applied this strat-
egy in Tg(cd41:EGFP) transgenic zebrafish embryos and exposed embryos at 9 hpf to adriamy-
cin for 48 hours. Given the toxicity of adriamycin, zebrafish embryos were immersed for 40
hours in the adriamycin-free medium after adriamycin exposure, before further manipulation.
Hence, all analyses were performed at 4 instead of 3 dpf. The zebrafish embryos were live-
screened for the nephrotic phenotype of pericardial edema at 4 dpf (Fig 5A). A dose and time
dependent increase in embryos with a phenotype of pericardial edema was observed (Fig 5B).
Quantitative PCR (qPCR) showed significantly reduced expression of nphs1 in adriamycin
exposed zebrafish embryos compared to control fish (Fig 5C). An evaluation of the glomerular
function was performed by injection of rhodamine-labeled 70 kDa dextran in 75 hpf old
embryos. In the adriamycin treated embryos, a statistically significant lower level of fluores-
cence intensity was detected 5 hours after injection in the retinal vascular bed of injected
embryos, indicating increased glomerular permeability and proteinuria (Fig 5D).
Similar to the published zebrafish model due to adriamycin exposure [22], reduced nephrin
RNA expression was confirmed in the adriamycin exposed Tg(cd41:EGFP) embryos. We fur-
ther evaluated the expression of both PACAP genes at 4, 5 and 6 dpf after exposure to
Fig 2. PACAP and ceruloplasmin protein levels in nephrin depleted zebrafish. (A) Western blots for
PACAP, ceruloplasmin, and β-actin (loading control) were performed using whole zebrafish lysates at 3 dpf
for nephrin depleted (100 μM Nephrin morpholino) compared to control embryos. (B) Signal intensity of
Western blot bands was measured using ImageJ software. Graphs represent means ± SD from two repeated
experiments. A representative blot is shown. Means were compared using a two-tailed unpaired Student t
test, but no significant difference was observed. Mo, nephrin morpholino injected; Co, control morpholino
injected.
https://doi.org/10.1371/journal.pone.0182100.g002
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adriamycin. Similar to the nephrin-injected morpholinos, only adcyap1a was significantly
downregulated upon the high dose of adriamycin (30 μM), while the expression of both
adcyap1b and vip remained unaffected (S2 and S3 Figs).
This model was further analyzed for PACAP and ceruloplasmin protein levels and throm-
bocyte formation. Western blot for PACAP was performed using total zebrafish lysates that
showed a reduced expression in nephrotic fish compared to controls (P< 0.05) (Fig 6). The
signal intensity for ceruloplasmin on Western blot was not significantly different between
nephrotic and control embryos (Fig 6).
Fig 3. Quantification of thrombocytes in nephrin depleted Tg(cd41:EGFP) transgenic zebrafish. (A)
LEFT: GFP-labeled thrombocytes and thrombocyte precursors are formed in the zebrafish caudal
hematopoietic tissue (CHT) region (white arrows) at 3 dpf. Representative pictures of the CHT region of a
control and a nephrin depleted (100 μM nephrin morpholino) embryo at 3 dpf are shown. No obvious
differences in thrombocyte numbers were observed. RIGHT: Pixel intensity was measured using ImageJ
software. The graph represents means ± SD from measurements in three embryos per condition. (B) LEFT:
Western blot for GFP and β-actin (loading control) was performed using total zebrafish lysates at 3 dpf. A
representative blot is shown. RIGHT: Signal intensity was measured using ImageJ software. The graph
represents means ± SD from measurements in two repeated experiments. (C) LEFT: Fluorescence-activated
cell sorter (FACS) analysis of control zebrafish lysates for CD41 positive cells was performed at 3 dpf.
MIDDLE: FACS analysis of morphant zebrafish lysates for CD41 positive cells was performed at 3 dpf.
RIGHT: A diagrammatic representation of the number of GFP-positive cells per 100,000 counted cells. For
each zebrafish lysate, 500,000 cells were counted and analyzed. Graphs represent means ± SD from three
repeated experiments performed in duplicate. Mo, nephrin morpholino injected; Co, control morpholino
injected; SCC, side scatter; GFP, green fluorescent protein.
https://doi.org/10.1371/journal.pone.0182100.g003
PACAP in nephrotic syndrome zebrafish
PLOS ONE | https://doi.org/10.1371/journal.pone.0182100 July 31, 2017 8 / 18
GFP-labeled thrombocytes quantified by fluorescence microscopy revealed no differences
after quantification of pixel intensity (Fig 7A) and western blot for GFP expression was similar
in all embryo lysates (Fig 7B). Western blots for PACAP, ceruloplasmin, and GFP were
repeated at 5 and 6 dpf to investigate a time-dependent effect. However, these experiments
remained similar to the data obtained for 4 dpf.
Similar to the nephrin depleted embryos, we evaluated whether PACAP could have an
effect on the phenotype of the adriamycin exposed embryos. We conducted independent series
of experiments through the co-injection of the PACAP splicing morpholinos (adcyap1a and
adcyap1b) or the human PACAP-38 peptide (5μM) and next exposed the different groups to
either 0, 10 or 30 μM of adriamycin starting from 9 hpf until 57 hpf as previously described.
Compared to the adriamycin only exposed embryos, the injection with PACAP morpholinos
had a devastating effect on both the 10 and 30 μM adriamycin exposed embryos and the effect
was progressive between 4 dpf and 6 dpf (Fig 8A and 8B). Interestingly, human PACAP-38
could rescue the toxic phenotype induced by both concentrations of adriamycin (Fig 8C).
Discussion
The initial aim of this study was to generate a nephrotic syndrome animal model to evaluate
the role of PACAP deficiency in the increased risk of arterial thrombosis that was detected in
human NS patients. As our observations in humans showed more pronounced PACAP
Fig 4. PACAP morpholino suppression and PACAP-38 rescue in nephrin depleted embryos. (A)
Representative larvae of the phenotypes observed in different groups with or without PACAP (adcyap1a and
adcyap1b) morpholinos injections (100 μM each). (B) Approximately 100 injected embryos per condition were live-
screened at 4 dpf and assigned to a phenotype category. Compared to the control morpholino injection alone,
PACAP morpholinos produced a harmful effect when injected together with the control morpholino and a devastating
effect with the nphs1 morpholino. (C) Representative larvae of the phenotypes observed in different groups with
human PACAP-38 injection (5μM). (D) Approximately 100 injected embryos per condition were live-screened at 4
dpf and assigned to a phenotype category. Human PACAP-38 could rescue to a great extent the PACAP morpholino
injected embryos; however, they produced no beneficial effect on the nphs1 morpholino injected embryos.
https://doi.org/10.1371/journal.pone.0182100.g004
PACAP in nephrotic syndrome zebrafish
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deficiency and increased platelet counts in CNS compared to INS [9], we decided to use a CNS
animal model rather than a model mimicking minimal change nephrotic syndrome (MCNS)
or focal segmental glomerulosclerosis (FSGS). As mentioned previously, transgenic CNS
rodent models are not suitable because of early lethality after birth [28]. An endogenous
nephrin knockout mouse model, with podocyte-specific, doxycycline-inducible expression of
rat nephrin has later been developed [29]. Doxycycline-induced rat nephrin expression imme-
diately after birth could rescue nephrin-deficient mice from perinatal lethality. This model
shows proteinuria from the third week after birth, but considering the induced nephrin
expression, it is not a pure CNS model. We used zebrafish CNS models for our study, as
PACAP and ceruloplasmin levels, as well as thrombocyte counts, can be determined early after
maturation of the pronephros in such models.
As a genetic nephrin knockout zebrafish model is not available, a first CNS zebrafish model
was obtained using a nephrin targeting morpholino. Nephrin downregulation was confirmed
in the nephrin morphant Tg(cd41:EGF)model, as previously described [21]. Distinct from our
findings in human CNS patients [9], we did not observe PACAP peptide deficiency or
increased thrombocyte numbers in these nephrin depleted embryos. On the other hand, when
we tested the gene expression of both zebrafish PACAP genes in nephrin depleted embryos
Fig 5. Phenotype analysis, nephrin expression and evaluation of glomerular function in adriamycin exposed zebrafish. (A) Different
categories of phenotype were defined in the adriamycin exposed embryos at 4 dpf: embryos with a normal phenotype, embryos with visible
pericardial edema (white arrow) and dysmorphic or dead embryos. (B) 100 embryos per condition were live-screened at 4 dpf and assigned to a
phenotype category. Increasing adriamycin concentrations in the culture medium were associated with an increasing percentage of embryos with
pericardial edema. (C) qPCR was performed using total RNA from control and adriamycin exposed embryos at 4 dpf. A significantly decreased
expression of nephrin (corrected for housekeeping gene elfa) was observed in the adriamycin exposed embryos compared to the control fish. The
experiment was performed twice in triplicate. Bars represent means ± SD. * P<0.05 in comparison to condition without the addition of adriamycin.
(D) Rhodamine-labeled 70 kDa dextran was injected in the cardiac venous sinus of 75 hpf old embryos. LEFT: A representative
immunofluorescence picture of a control embryo immediately after injection shows the distribution of fluorescence through the vascular system of
the zebrafish larva. A dose-dependent diminishing effect of adriamycin on fluorescence recorded in the fish eye 5 hours after injection was
observed. Representative images of the eye from 0, 10 and 30 μM adriamycin treated embryos 5 hours after injection are shown. RIGHT: A
diagrammatic representation shows the quantification of the mean fluorescence intensity ± SD recorded in the retinal vascular bed. * P < 0.05 in
comparison to condition without the addition of adriamycin.
https://doi.org/10.1371/journal.pone.0182100.g005
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during the first 3 days of development we found a significant downregulation of adcyap1a but
not adcyap1b compared to the controls (S2 Fig). Using whole mount in situ hybridization,
Alexandre et al reported that both genes were expressed mainly in the brain and spinal cord
during early development and that adcyap1b gene was higher expressed (4 folds) compared
to the adcyap1a gene [30]. This might explain the lack of PACAP deficiency on the protein
level in this model.
Another possible explanation is that the short duration of proteinuria with subsequent mor-
tality of the embryos was not sufficient for developing PACAP and ceruloplasmin deficiency.
Moreover, the phenotype of pericardial edema was achieved only in a small percentage of
nephrin depleted embryos. A large percentage of embryos still had a normal phenotype at
lower concentrations of injected nephrin morpholino, while high mortality was observed at
higher concentrations.
The downregulation of both adcyap1a and vip genes in the nephrin depleted embryos
might point to a shared perturbation of their activities in CNS; however, this perturbation
doesn’t induce a palpable effect on thrombopoiesis in the zebrafish. It would be interesting to
study the hemodynamics and the effects of VIP on thrombopoiesis and platelet function in
human CNS patients, especially that the outcome effect is easily observable [9].
A second recently described CNS zebrafish model was also studied [22]. Adriamycin expo-
sure suppresses nephrin expression and subsequently causes functional impairment of the glo-
merular filtration barrier, leading to proteinuria and pericardial edema early after fertilization,
similar to human CNS. We examined the possibility of using adriamycin exposed Tg(cd41:
Fig 6. PACAP and ceruloplasmin protein levels in the adriamycin treated zebrafish. (A) Western blot for
PACAP, ceruloplasmin, and β-actin (loading control) was performed using total zebrafish lysates. A
representative blot is shown. (B) Pixel intensity of Western blot bands was measured using ImageJ software.
Graphs represent means ± SD of signal intensity from two repeated experiments. * P < 0.05 (two-tailed
unpaired Student t test).
https://doi.org/10.1371/journal.pone.0182100.g006
PACAP in nephrotic syndrome zebrafish
PLOS ONE | https://doi.org/10.1371/journal.pone.0182100 July 31, 2017 11 / 18
EGF) zebrafish embryos as an alternative model to study the effect of PACAP on thrombocyte
formation in NS. We confirmed nephrin depletion, impaired function of the glomerular filtra-
tion barrier, and a dose and time dependent increase of pericardial edema in adriamycin
exposed embryos, as previously described [22]. At the RNA level, only adcyap1a was downre-
gulated upon higher dose of adriamycin (30 μM) and relatively late at 6 dpf. Since PACAP is
deficient at the protein level earlier in this model we think that inhibitory effects of adriamycin
on peptide synthesis or the direct peptide loss through the kidney due to proteinuria may play
the major role in this deficiency.
On the other hand, ceruloplasmin levels and GFP-labeled thrombocyte numbers remained
unchanged with adriamycin exposure. We previously observed that children with INS have
mildly decreased plasma PACAP levels, but maintain normal serum ceruloplasmin levels and
demonstrate increased platelet counts only in a subgroup of the patients [9]. Hence, the adria-
mycin exposed zebrafish model seems to mimic the observations in human INS rather than
CNS. We hypothesized that a longer duration of nephrosis might be necessary to affect mega-
karyopoiesis and platelet count. Furthermore, in humans with CNS, we observed low or nor-
mal platelet counts immediately after birth, slowly increasing within 1 or 2 weeks until they
Fig 7. Quantification of thrombocytes in adriamycin treated zebrafish. (A) LEFT: GFP-labeled
thrombocytes and thrombocyte precursors are formed in the zebrafish caudal hematopoietic tissue (CHT).
Representative pictures of the CHT region at 4 dpf of embryos exposed to adriamycin 0, 10 and 30 μM are
shown. No obvious difference in thrombocytes was observed between the controls and the adriamycin
exposed fish. RIGHT: Pixel intensity was measured using ImageJ software. The graph represents
means ± SD from measurements in three embryos per condition. No significant difference was observed
between adriamycin exposed and control embryos. (B) LEFT: Western blot for GFP and β-actin (loading
control) was performed using total zebrafish lysates at 4 dpf. A representative blot is shown. RIGHT: Signal
intensity was measured using ImageJ software. The graph represents means ± SD from measurements in
two repeated experiments. No significant difference was observed between adriamycin exposed and control
embryos.
https://doi.org/10.1371/journal.pone.0182100.g007
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reached levels of 500–600 x 109/L [9]. However, also for the adriamycin exposed zebrafish lar-
vae that were analyzed at 5 and 6 dpf, they showed no change in ceruloplasmin levels or
thrombocyte counts.
Adriamycin is known to be a cytotoxic drug. It increases oxidative stress and inhibits
nucleic acid and protein synthesis of many essential enzymes and proteins [31]. Some of these
might be involved in PACAP synthesis. So, although adriamycin causes nephrin downregula-
tion and nephrotic syndrome in the zebrafish, it might not fully mimic the pathophysiologic
state of the human NS.
Like other cytotoxic drugs, adriamycin can also cause myelosuppression in humans. Leuko-
penia is the most common, but moderate thrombocytopenia can also rarely occur and in a
Fig 8. PACAP morpholino suppression and PACAP-38 rescue in adriamycin exposed embryos. (A) Approximately 100
embryos exposed to adriamycin (0, 10 or 30 μM) in the swimming water (no injections), were live-screened at 4, 5 and 6 dpf and
assigned to a phenotype category. (B) Approximately 100 embryos injected with PACAP morpholinos (adcyap1a and adcyap1b,
100 μM) were exposed to adriamycin (0, 10 or 30 μM) and then live-screened at 4, 5 and 6 dpf. PACAP morpholinos had a
devastating effect on survival and morphology of the adriamycin exposed embryos. (C) Approximately 100 embryos injected with
the human PACAP-38 peptide (5 μM) were exposed to adriamycin (0, 10 or 30 μM) and then live-screened at 4, 5 and 6 dpf.
Human PACAP-38 could rescue the nephrotic phenotype in zebrafish with adriamycin exposure especially with the higher
concentration (30 μM).
https://doi.org/10.1371/journal.pone.0182100.g008
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dose-dependent effect [32]. Hence, a direct inhibitory effect of adriamycin on thrombocyte
formation in this zebrafish model cannot be excluded. A dose-dependent decrease of GFP-pos-
itive thrombocytes might then be expected and could counteract the effect of the demonstrated
PACAP deficiency at this early stage.
As adriamycin can also cause cardiomyopathy in humans [33] and adult zebrafish [34], the
question arose if the observed pericardial edema in the adriamycin exposed fish could be
explained by cardiac toxicity, besides proteinuria. However, the cardiac phenotype in this
model was previously studied in detail. Embryos exposed to low concentrations of adriamycin
did not show any signs of cardiac toxicity or vascular abnormalities. Only higher concentra-
tions (>40 μM) gave rise to morphological and functional cardiac changes and dysmorphic
blood vessels. Moreover, dose-dependent proteinuria, associated with increasing cardiac
edema was demonstrated, enforcing the causal relationship between proteinuria and edema in
this model [22].
The explanation for the fact that our platelet findings for human CNS could not be repli-
cated in these zebrafish CNS models, could be the important differences between thrombocyte
formation in zebrafish and platelet formation in humans. The early process of hematopoiesis,
including the formation of hematopoietic stem cells and megakaryocytes (or thrombocyte pro-
genitors for the zebrafish), is comparable in both species [35]. However, zebrafish thrombo-
cytes are very different from human platelets, as they remain nucleated [36]. The final
maturation process from thrombocyte progenitor to thrombocyte seems to be different in zeb-
rafish when compared to proplatelet formation from megakaryocytes in mammals. The exis-
tence of a zebrafish equivalent of such proplatelet-forming megakaryocyte that undergoes
fragmentation of its cytoplasm to produce platelets has never been demonstrated. If PACAP
deficiency exerts its effect during this late stage of megakaryopoiesis in humans [37], this could
be another reason why our observations in humans were not reproducible in studied CNS zeb-
rafish models.
One of the major findings of this study was revealing the renoprotective role of PACAP
against adriamycin induced toxicity in the zebrafish. PACAP has previously been reported as
protective against the cardiotoxic effects of adriamycin in vitro in rat cardiomyocyte culture
and in vivo in mice [38,39]. It has also been reported to have renoprotective effects in murine
models against multiple renal injuries as cisplatin-induced toxicity and contrast and diabetic
nephropathies [40–42]. However, this is the first study that demonstrated a renoprotective
effect of PACAP in the zebrafish. The fact that PACAP couldn’t rescue the phenotype of the
nephrin morpholino further confirms our previous observation that adriamycin exerts its
renal toxicity not only through nephrin downregulation but also through other mechanisms
that can cause PACAP deficiency and therefore might be susceptible to PACAP therapy.
In conclusion, we established in this study two different CNS models in Tg(cd41:EGFP)
transgenic zebrafish, by injection of a nephrin morpholino or exposure to adriamycin. In the
nephrin depleted zebrafish model, neither PACAP deficiency nor increased thrombocyte
counts were observed. PACAP deficiency was observed in the adriamycin exposed model;
however, thrombocyte counts were not increased. We also confirmed that PACAP splicing
morpholinos worsened the phenotype in both CNS models and that human PACAP-38 pep-
tide could rescue the nephrotic phenotype in the adriamycin exposed model, but not in the
nephrin depleted model. We conclude that none of the studied CNS larval zebrafish models
were suitable for investigating the role of PACAP deficiency in megakaryopoiesis in CNS and
that the adriamycin exposed model is a more suitable model to study PACAP deficiency and
rescue in the zebrafish.
For future research, PACAP deficiency effect on megakaryopoiesis can be studied in other
mammalian animal models of NS, such as the adriamycin treated mice [43]. On the other
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hand, the PACAP deficient zebrafish model reported in our study can be beneficial in the
study of other physiological and pathological mechanisms involving PACAP in the zebrafish,
such as brain development [44], energy homeostasis [45] and neuronal injury [46].
Supporting information
S1 Fig. Determining the PACAP-38 peptide rescue concentration. (A) Amino acid align-
ment between the human PACAP-38 and zebrafish PACAP-38. (B) Phenotype categorization
after the injection of different concentrations of human PACAP-38 with adcyap1a and
adcyap1b morpholinos (Minimum of 50 embryos were injected per condition).
(TIF)
S2 Fig. Relative gene expression of adcyap1a and adcyap1b in the nephrin depleted (A,B)
and the adriamycin exposed (C,D) CNS models.
(TIF)
S3 Fig. Relative gene expression of vip in the nephrin depleted (A) and the adriamycin
exposed (B) CNS models.
(TIF)
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